当前位置: 首页 >> 检索结果
681. [Arterial chemoinfusion for treatment of unresectable malignant tumors of the liver].683. [The blood-stimulating effect of granulocyte colony-stimulating factor during cytostatic exposure].
作者: E D Gol'dberg.;A M Dygaĭ.;V V Zdanov.;G N Krivopalova.;V I Masycheva.;N M Pustoshilova.;N S Pushkareva.;E V Simanina.;S A Sinichkina.
来源: Biull Eksp Biol Med. 1999年127卷8期194-9页 684. [Targets of antileukemia agents: molecular mechanisms of mercaptopurine action].685. [Study of the toxicity of pyrophosphate (an ingredient of Olipiphat)].
No signs of toxicity of pyrophosphate as an ingredient of olipiphat were found in acute and chronic experiments using mice, rats, guinea pigs, rabbits and dogs. Mild antitumor action was recorded.
686. [Effect of Ruboxyl (nitroxyl derivative of daunorubicin) on hepatic metastases of colorectal carcinoma].
作者: N P Konovalova.;L M Volkova.;D Codacci-Pisanelli.;P Seminara.;F Franchi.
来源: Vopr Onkol. 2000年46卷4期438-41页
Inhibition by ruboxyl, a nitroxyl derivative of daunorubicin, source preparation and 5-fluorouracil was compared in metastases of experimental colorectal carcinoma to murine liver. The indices of metastasis inhibition were 84.43 and 70%, respectively. In rats receiving the drugs by continuous intravenous infusion for 7 days, the number of metastases was reduced (ruboxyl--1.0 +/- 1.4; 5-fluorouracil 3.2 +/- 1.3.
687. [Effect of cycloferon on the evolution of cervical and vaginal cancer in mice].
作者: M A Zabezhinskiĭ.;E A Zarinova.;I G Popovich.;A L Kovalenko.;V N Anisimov.
来源: Vopr Onkol. 2000年46卷4期433-7页
7,12-dimethylbenz(a)anthracene (DMBA) was given by tampon intravaginally to 198 mice CBA (9 groups), twice a week, for 2 months, to induce cervical and vaginal tumors. Cycloferon (CF)--an interferon inductor--was injected in study group animals subcutaneously and/or introduced into the vagina by smear, in 2-month courses. CF was given during DMBA treatment or after it. Controls were injected saline solution, sc, and/or received placebo smears, i.v. The experiment was run for 6 months. Tumor incidence in controls was 35-70%. Carcinogenesis tended to slow down when CF was given during DMBA treatment. Neoplasia was found in 38-57%. More marked anticarcinogenic effect was registered in animals receiving CF on termination of DMBA application: tumor frequency dropped to 29-41%, with malignant tumor number significantly reduced.
688. [High-dose thiotepa chemotherapy in children].
作者: D G Izhogin.;V K Boiarshinov.;I S Dolgonolov.;M Ia Iankelevich.;E A Ptushkina.;G L Mentkevich.
来源: Vopr Onkol. 2000年46卷4期401-6页
High-dose thiotepa (800-900 mg/m2) polychemotherapy following combined treatment resulted in high toxicity and lethality. 600 mg/m2 proved optimal for double-conditioning regimens since it exerted antitumor effect without causing fatal complications.
689. [Study of the transmission mechanism of mitogen signals of growth factors is the foundation for the development of new antineoplastic agents in pediatric oncology].
作者: N E Kushlinskiĭ.;E S Gershteĭn.;Iu N Solov'ev.;K O Dumbraĭs.;L A Durnov.;N N Traneznikov.
来源: Vopr Onkol. 2000年46卷4期385-94页 690. [Phosphinic analog of methionine inhibits growth of leucosis cell L1210 and transforms to phosphinic analog of S-adenosylmethionine].
作者: R M Khomutov.;Iu N Zhukov.;A R Khomutov.;E N Khurs.;D L Kramer.;J T Miller.;C W Porter.
来源: Bioorg Khim. 2000年26卷9期718-20页
A phosphinic analogue of methionine bearing a phosphinic H(OH)(O)P fragment in place of the carboxyl group inhibited the growth of the L1210 cells and was intracellularly transformed to the phosphinic analogue of S-adenosylmethionine.
691. [Biologically active fragment of the differentiation factor from HL-60 cell line. Identification and properties].
作者: I A Kostanian.;M V Astapova.;E V Navolotskaia.;T N Lepikhova.;S M Dranitsyna.;G B Telegin.;I L Rodionov.;L K Baĭdakova.;Iu A Zolotarev.;I M Molotkovskaia.;V M Lipkin.
来源: Bioorg Khim. 2000年26卷7期505-11页
Six-membered peptide fragment TGENHR (HLDF-6) was identified in the HL-60 cell culture of human promyelocyte leukemia treated with retinoic acid when studying the differentiation factor HLDF of this cell line. HLDF-6 retains the ability of the full-size factor to induce the differentiation and arrest the proliferation of the starting HL-60 cells. It was shown that the synthetic peptide HLDF-6 has no specific receptors on the surface of the HL-60 cells but can affect the binding of interleukin IL-1 beta, a cytokine involved in proliferation, to the cell surface. It was found on a model of transplantable NSO myeloma that HLDF-6 has an antitumor activity.
692. [The therapeutic efficacy and toxicity of the liposomal form of daunorubicin (Daunoxome) in lymphosarcoma patients].
To evaluate toxicity and efficacy of CDxOP regimen in the treatment of primary non-Hodgkin's lymphoma (PNHL).
693. [Hemostatic changes during the treatment of acute promyelocytic leukemia with all-transretinoic acid].
作者: N A Medvedeva.;V V Cherepanova.;L N Tarasova.;A V Kudriavtseva.;A I Kostin.;O R Kolupaeva.
来源: Ter Arkh. 2000年72卷7期27-31页
To study hemostasis in ATRA treatment of acute promyelocytic leukemia (APL).
694. [Low doses of alpha-interferon preparations in the treatment of patients with chronic myeloleukemia].
作者: K M Abdulkadyrov.;V Iu Udal'eva.;O A Rukavitsyn.;S S Bessmel'tsev.
来源: Ter Arkh. 2000年72卷7期22-7页
To compare the effects of low-dose alpha-interferons with those of cytostatics (hydroxyurea or myelosan) on survival of patients and duration of chronic phase of chronic myeloid leukemia (CML).
695. [Betaleukin (human recombinant interleukin-1 beta)--a new effective leukopoiesis stimulant and protector in the combined chemotherapy of malignant tumors].
作者: M L Gershanovich.;L V Filatova.;S A Ketlinskiĭ.;A S Simbirtsev.
来源: Vopr Onkol. 2000年46卷3期354-60页 696. [The optimization of a plan for the photodynamic therapy of sarcoma M1 using photosens].
作者: T S Lagoda.;M A Kaplan.;Ia V Krivosheev.;L P Zhavoronkov.;M B Bokova.
来源: Vopr Onkol. 2000年46卷3期327-31页
The study established the importance of optimal dosage, concentration and mode of administration of the drug Fotosens for the effectiveness of photodynamic therapy of tumor. Of similar importance is the interval between administration and irradiation to potentiate the drug's action. Failure to consider the latter factor may lower the effect dramatically or even reverse it. Experimental findings point to high antitumor potency of the drug. Preference should be given to injecting relatively low concentrations along the periphery of tumor, thus avoiding the undesirable cytostimulating effect and toxicity of Fotosens and saving on the drug. The potential of the treatment as a component of "white light" photodynamic therapy is discussed.
697. [A comparative randomized phase-II study of Xeloda (capecitabine) and paclitaxel in patients with breast cancer progressing after anthracycline antibiotics].
作者: V M Moiseenko.;S M O'Reilly.;D C Dalbot.;S Van Belle.;R J Gordon.;T Griffin.;B Osterwalder.
来源: Vopr Onkol. 2000年46卷3期285-9页
A randomized study of the effectiveness of treatment with capecitabine (Xeloda) (22) and paclitaxel (taxol) (19) was carried out in breast cancer patients resistant to anthracycline antibiotic drugs. Capecitabine and paclitaxel showed comparable effectiveness, although the former appeared less toxic, particularly, in hematologic complication situations. Therefore, it may be administered to out-patients who previously received several courses of chemotherapy.
698. [The probability of the carcinogenic risk of using nitrosomethylurea for treating cancer patients].
The results of nitrosomethylurea (NMU) chemotherapy in 12 patients suffering Hodgkin's disease were evaluated. Significant effect was seen in 73.3% with 54.5% in complete remission. Out of 37 survivors for more than 5 years, 26 have survived tumor-free for 7-22 years. Secondary tumor disease (acute lymphoblastic leukemia) was diagnosed in one cases 14 years after diagnosis of Hodgkin's disease stage IIb, which was treated with radiation and standard chemotherapy, and 10 years after combination chemotherapy using NMU as a component for relapse. There is no evidence suggesting any risk of secondary tumor among NMU-treated cancer patients.
699. [Effect of polyamine synthesis inhibitors separately and in combination with epidermal growth factor on fusion of lysosomes with phagosomes and F-actin level in mouse peritoneal macrophages].
Effects of polyamine (PA) synthesis inhibitors--alpha-difluoromethylornithinchloride (DFMO) and alpha-methylornithinchloride (MO)--separately or in combination with the epidermal growth factor (EGF)--on lysosome-phagosome fusion (P-LF) and F-actin content in murine peritoneal macrophages were studied using fluorescent dye Acridine orange for lysosome labelling, FITC-phalloidin for F-actin, and yeast cells as a target. DFMO and MO significantly inhibited P-LF and decreased F-actin content in murine peritoneal macrophages. A combination of DFMO and MO with EGF failed to inhibit P-LF or to decrease F-actin content in these cells. The results obtained with DFMO and MO suggested new cellular targets of their effects. These results may be extended to cancer research to provide a rationale for clinical trials using combinations of EGF with DFMO or MO.
700. [Some indices of gastrointestinal tract status in children cured fro malignant neoplasms].
作者: E I Boĭchenko.;G E Zaeva.;N M Ivanova.;Iu V Pashkov.;I V Kaminskaia.
来源: Vestn Ross Akad Med Nauk. 2000年6期37-8页
A total of 2255 individuals who cured from oncological diseases in childhood in Moscow in 1978 to 1997 have been studied. Most (60%) children undergone special treatment have serious visceral abnormalities. The authors examined the negative impact of a special treatment on the gastrointestinal mucosa and changes in its function after termination of special therapy in 79 cured patients. The most common diagnosed abnormalities included biliary dyskinesis (17-20%), dysbacterioris (16%), gastritis (7%). No abnormal gastrointestinal changes were detected in 37%.
|